What is XEFO 8mg used for?

Xefo and associated names, 4mg and 8mg film-coated tablets, 8mg rapid film coated tablet, and 8mg powder and solvent for solution for injection, is a non-steroidal anti-inflammatory drug (NSAID), used for short-term relief of acute mild to moderate pain, symptomatic relief of pain and inflammation in osteoarthritis and …

What is the difference between XEFO and XEFO rapid?

The Cmax for Xefo Rapid film-coated tablets is higher than Cmax for Xefo film-coated tablets and equivalent to Cmax for the parenteral formulation of lornoxicam. The absolute bioavailability of Xefo Rapid film-coated tablets is 90-100% which is equivalent to Xefo film-coated tablet.

Why is lornoxicam prescribed?

Lornoxicam is used for pain relief. It relieves pain and inflammation in conditions like rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID).

What are the side effects of lornoxicam?

The most frequent adverse effects of lornoxicam include nausea, dyspepsia, indigestion, abdominal pain, vomiting, and diarrhoea. These symptoms have generally occurred in less than 10% of patients in available studies. Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.

What does Xeforapid treat?

Xefo Rapid is a non-steroidal anti-inflammatory drug and antirheumatic drug (NSAID) of the oxicam class. It is intended for short term treatment of acute mild to moderate pain.

What does XEFO contain?

The active substance: XEFO 4 tablets: Each film-coated tablet contains 4 mg lornoxicam. XEFO 8 tablets: Each film-coated tablet contains 8 mg lornoxicam.

When should I take XEFO 8mg?

The usual dose for adults is 8-16 mg divided in doses of 8 mg: 8 mg taken twice a day or 16 mg taken once a day. On the first day you take Xefo Rapid the dose can be 16 mg followed by 8 mg 12 hours later. After the first day do not take more than 16 mg a day.

Is lornoxicam stronger than ibuprofen?

Conclusion: Ibuprofen 400 mg and lornoxicam 8 mg were rated as equal and effective pain treatment medication after wisdom tooth surgery. In comparison, neither of the drugs provided clinical advantages nor did side effects occur more frequently after one of the analgesics.

Is lornoxicam available in USA?

Nycomed (now Takeda Pharmaceuticals International) has developed lornoxicam as an oral and injectable treatment for acute pain, and it is available in 22 countries outside the USA, including Europe and Japan.

What is Lornoxicam 8mg for?

Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that is used as a painkiller (analgesic). A high level of pain relief is experienced by about 45% of those with moderate to severe postoperative dental pain after a single dose of lornoxicam 8 mg, compared to about 10% with placebo.

Does lornoxicam make you sleepy?

It may cause drowsiness or dizziness, do not drive a car or operate machinery while taking this medication.

When should I take XEFO?

Xefo Rapid with food and drink Xefo Rapid film-coated tablets are intended for oral use. Take this medicine before meals with a sufficient amount of liquid. Taking this medicine with food is not recommended because this may reduce its effectiveness.

What kind of drug is XEFO rapid 8mg?

Each Xefo Rapid Tablet contains Lornoxicam 8mg Xefo Rapid is a non-steroidal anti-inflammatory drug with analgesic properties. It belongs to the oxicam class of drugs. The mode of action of Xefo Rapid is partly based on inhibition of prostaglandin synthesis (inhibition of the enzyme cyclooxygenase).

What kind of interactions are there with XEFO rapid?

Xefo Rapid (like other non-steroidal anti-inflammatory drugs dependent on the cytochrome P450 2C9 (CYP2C9) isoenzyme) has shown interactions with known CYP2C9 inducers and inhibitors (such as tranylcypromine and rifampicin ).

Is it safe to take XEFO rapid during pregnancy?

Although no evidence of any teratogenic potential was found, Xefo Rapid film-coated tablets are contraindicated in pregnancy as no adequate clinical experience in humans has been established.

When was the European Commission decision on XEFO issued?

The scientific conclusions are provided in Annex II together with the amended SPC, labelling and package leaflet in Annex III. A Decision was issued by the European Commission on 29 May 2007.